Icotinib versus Cisplatin Plus Docetaxel as Adjuvant Chemotherapy in Patients with Stage II (N1+) Non-Small Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study

PURPOSE: The superior efficacy of first-line treatment with icotinib over that of standard chemotherapy has been well demonstrated in patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation. However, whether icotinib is superior to cisplat...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Saibo, Wang, Shijie, Li, Wenshan, Chai, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7896780/
https://www.ncbi.nlm.nih.gov/pubmed/33623394
http://dx.doi.org/10.2147/OTT.S290636

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7896780/
https://www.ncbi.nlm.nih.gov/pubmed/33623394
http://dx.doi.org/10.2147/OTT.S290636

Ejemplares similares